Publications by authors named "S Venneti"
Article Synopsis
- H3K27M diffuse midline gliomas (DMG) consist of two main types of cells: less-differentiated oligodendrocyte precursor-like stem cells and more differentiated astrocyte-like cells.
- Researchers created models representing these cell types and used various profiling techniques to understand their distinct metabolic programs, identifying specific weaknesses in each type.
- The study found that astrocyte-like cells are more prone to a type of cell death called ferroptosis, while oligodendrocyte precursor-like cells are sensitive to statins and inhibitors of mitochondrial function, suggesting targeted therapies could improve treatment outcomes for patients with these tumors.
Article Synopsis
- Radiotherapy is the main treatment for a deadly type of brain cancer in kids called diffuse midline glioma (DMG), which has a special genetic mutation (H3K27M).
- Researchers found that this mutation makes the tumors weaker against radiation when combined with a medicine called PARP inhibitor (like olaparib), which can help fight the cancer.
- The study showed that using PARP inhibitors with radiotherapy also boosts the immune system, allowing it to attack the cancer cells better, which could be an important new treatment for kids with DMG.
Article Synopsis
- Diffuse midline gliomas (DMGs) are aggressive brain tumors in children, and imipridones ONC201 and ONC206 show promise as treatments despite limited effectiveness on their own.
- A study reveals that GABA accumulation occurs quickly after ONC206 treatment, serving as an early metabolic biomarker for tracking drug effectiveness in mice models.
- GABA not only helps protect tumor cells from stress-induced cell death but also presents a means for non-invasive monitoring and potential improvements in personalized treatment approaches for DMG patients.
Article Synopsis
- Diffuse midline gliomas (DMG), particularly the H3K27M subtype, are aggressive brain tumors resistant to standard radiation treatments due to mutations affecting metabolism.
- Research shows that these tumors have a unique dependence on purine synthesis pathways, which are crucial for their growth and survival, particularly in the context of radiation therapy.
- Inhibiting purine synthesis, especially through targeting specific enzymes like HGPRT, enhances the effectiveness of radiation treatments and reduces tumor growth, suggesting potential therapeutic strategies for DMG-H3K27M.
Article Synopsis
- Pediatric high-grade gliomas (pHGGs), particularly diffuse midline gliomas (DMGs), are highly aggressive tumors with low survival rates, yet the combination of Delta-24-RGD and ONC201 has shown potential for enhanced treatment efficacy.
- In laboratory and mouse model studies, the combination treatment did not alter virus replication but demonstrated a synergistic or additive cytotoxic effect, leading to increased DNA damage and metabolic disruptions in tumor cells.
- Additionally, the combination treatment improved survival rates in mice models and led to a shift in the tumor microenvironment towards a more proinflammatory state, indicating a stronger immune response against the tumors.
